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Signaling via cGMP-dependent protein kinase is the
major pathway of the NO/cGMP cascade in vascular
smooth muscle (SM), heart, CNS, and other cells. cGMP-
dependent protein kinases (cGK) are serine/threonine
kinases that are widely distributed in eukaryotes. Two
genes – prkg1 and prkg2 - code for cGKs, namely cGKI
and cGKII. In mammals, two isozymes, cGKIa and
cGKIb, are generated from the prkg1 gene. The cGKI iso-
zymes are prominent in all types of smooth muscle, pla-
telets and specific neuronal areas such as cerebellar
Purkinje cells, hippocampal neurons, and the lateral
amygdala. The cGKII prevails in the secretory epithelium
of the small intestine, the juxta-glomerular cells, the
adrenal cortex, the chondrocytes, and in the nucleus
suprachiasmaticus. Both cGKs are major down- stream
effectors of many, but not all signalling events of the
NO/cGMP and the ANP/BNP/CNP/cGMP pathways.
cGKI relaxes smooth muscle tone and prevents platelet
aggregation, whereas cGKII inhibits renin secretion,
chloride/water secretion in the small intestine, the reset-
ting of the clock during early night and endochondreal
bone growth. cGKs are involved in cardiovascular and
non-cardiovascular processes and are modulators of cell
growth and many other functions.
Recent evidence suggest that vascular smooth muscle
relaxation is not affected by cGK-dependent phosphoryla-
tion of smooth muscle expressed TRPC channels, but by
cGK-dependent inhibition of TRPC-6 in endothelial cells
and attenuation of endothelial release of smooth muscle
relaxing factors. Angiotensin increases blood pressure and
induces cardiac hypertrophy. Hypertrophy is reduced in
sildenafil treated wild type mice but not in beta rescue
mice. This suggests that the sildenafil effects are mediated
by inhibition of a cGMP hydrolysing phosphodiesterase.
Restricted evidence supports the notion that sildenafil
affects cGMP levels in cardiomyofibroblasts and/or in car-
diac endothelial cells.
It will be shown that cGK are essential modulators of
many regulatory processes.
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